Overall survival with warfarin versus low-molecular-weight heparin in cancer-associated thrombosis

被引：0
|
作者：
Patell, R. [1 ,2 ]
Chiasakul, T. [1 ,2 ,3 ,4 ]
Redd, R. [5 ]
Khan, A. M. [1 ,2 ]
McCarthy, E. P. [6 ,7 ,8 ]
Neuberg, D. [5 ]
Zwicker, J. I. [1 ,2 ]
机构：
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol, Boston, MA 02115 USA
[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Hemostasis & Thrombosis, Boston, MA 02115 USA
[3] Chulalongkorn Univ, Fac Med, Dept Med, Div Hematol, Bangkok, Thailand
[4] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Hebrew SeniorLife, Hinda & Arthur Marcus Inst Aging Res, Boston, MA USA
[7] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Gerontol, Boston, MA 02115 USA
[8] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med, Boston, MA 02115 USA
来源：
THROMBOSIS RESEARCH | 2021年 / 200卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-97
引用
收藏
页码：S72 / S73
页数：2
相关论文
共 50 条
  • [1] Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis
    Chiasakul, Thita
    Redd, Robert
    Patell, Rushad
    Khan, Adeel M.
    McCarthy, Ellen P.
    Neuberg, Donna
    Zwicker, Jeffrey, I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (11) : 2825 - 2834
  • [2] Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil
    Lopes, Danilo G.
    Tamayo, Arturo
    Schipp, Bernhard
    Siepmann, Timo
    THROMBOSIS RESEARCH, 2020, 196 : 4 - 10
  • [3] Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis
    Chai-Adisaksopha, Chatree
    Cheah, Matthew
    AlKindi, Said Y.
    Iorio, Alfonso
    Crowther, Mark A.
    Linkins, Lori Ann
    BLOOD, 2015, 126 (23)
  • [4] Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study
    Seaman, Siwan
    Nelson, Annmarie
    Noble, Imon
    PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 453 - 461
  • [5] Low-molecular-weight heparin beyond 12 months in patients with cancer-associated thrombosis
    Lopez-Ruz, Sergio
    Barca-Hernando, Maria
    Marin-Romero, Samira
    Elias-Hernandez, Teresa
    Otero-Candelera, Remedios
    Jara-Palomares, Luis
    BRITISH JOURNAL OF CANCER, 2022, 127 (12) : 2234 - 2240
  • [6] Low-molecular-weight heparin beyond 12 months in patients with cancer-associated thrombosis
    Sergio Lopez-Ruz
    Maria Barca-Hernando
    Samira Marin-Romero
    Teresa Elias-Hernandez
    Remedios Otero- Candelera
    Luis Jara-Palomares
    British Journal of Cancer, 2022, 127 : 2234 - 2240
  • [7] Warfarin versus low-molecular-weight heparin therapy in cancer patients
    Zacharski, LR
    Prandoni, P
    Monreal, M
    ONCOLOGIST, 2005, 10 (01): : 72 - 79
  • [8] Low-molecular-weight heparin in thrombosis and cancer
    Mousa, SA
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2004, 30 : 25 - 30
  • [9] Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis
    Kang, Wei
    Huang, Caige
    Yan, Vincent K. C.
    Wei, Yue
    Shami, Jessica J. P.
    Li, Silvia T. H.
    Yang, Yu
    Ye, Xuxiao
    Tang, Junhan
    Lee, Shing Fung
    Lee, Victor H. F.
    Chan, Stephen L.
    El Helali, Aya
    Lam, Ka On
    Ngan, Roger K. C.
    Wong, Ian C. K.
    Chan, Esther W.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [10] Cancer-Associated Thrombosis: Role of Low-Molecular-Weight Heparins - Introduction
    Fareed, J
    Streiff, MB
    Hoppensteadt, D
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : S1 - S2
12345